CONSENT TO PARTICIPATE IN RESEARCH
The University of Mississippi [INVESTIGATOR_513581]:  A Mobile Intervention to Improve Uptake of PrEP for  
Southern Black MSM: Randomized Controlled  
Phase
Principal Investigator(s):  
Mississippi – Leandro Mena M.D., M.P.H. 
   University of Mississippi [INVESTIGATOR_513582], MS
Rhode Island – Laura Whiteley, M.D.
       Brown University 
       Providence, RI
Site(s): Open Arms Healthcare Center
_____________________________________________________
Introduction      
You are being invited to take part in this research project because you are a male age  
18-35 years (assigned male at birth) who is not currently taking pre-exposure  
prophylactic (PrEP) medication to prevent HIV
Purpose     
The purpose of this study is to evaluate if a mobile messaging intervention improves  
HIV-related knowledge and attitudes and attendance at PrEP appointments.
Procedures
If you agree to participate in this study, you will have three appointments over [ADDRESS_665342] appointment , you will complete a questionnaire regarding demographic  
information, sexual and drug behaviors, adherence to medical treatment, and HIV  
knowledge and attitudes. You may choose not to answer any questions that make you  
uncomfortable. 
University of Mississippi [INVESTIGATOR_513583]00003630
Protocol: 2017-0169
Approved: 05/05/2020
Expi[INVESTIGATOR_6054]: 05/04/[ADDRESS_665343] study appointment, y ou will be assigned, by [CONTACT_3364], to participate  
in one of the following two study groups:
(1) Group One: You will receive text with intervention content and follow-up  
questions over the next 4 weeks, on your cell phone. You will receive approximately  
8-16 text messages with links to web content and questions about PrEP and HIV  
Transmission, HIV prevention, and correcting misconceptions about HIV and PrEP.  
Texts will be sent twice a week over the next 4 weeks. 
OR
(2) Group Two:  You will be given feedback regarding your PrEP eligibility, current  
risk behavior, and future plans. You will also be given an informational handout about  
PrEP, shown a brief video, and given contact [CONTACT_513585]. 
All participants will have follow-up appointments at [ADDRESS_665344] you to confirm your research appointments prior to the scheduled week 5  
and week 17 dates. During these appointments we will ask you to complete a  
questionnaire about your demographic information, sexual and drug behaviors, how  
you manage your medication(s), and HIV knowledge and attitudes. We will also  
review your medical record at Open Arms Healthcare Center and collect information  
related to the PrEP care that you may receive during your participation in the study. 
Length of Participation
Your participation in this study will last about [ADDRESS_665345] your identity, 
we will keep personal information about you private.
Benefits  
University of Mississippi [INVESTIGATOR_513583]00003630
Protocol: 2017-0169
Approved: 05/05/2020
Expi[INVESTIGATOR_6054]: 05/04/[ADDRESS_665346] to be enrolled in this study to receive treatment or information about  
HIV or PrEP. If you choose not to participate in this study, information about PrEP and  
HIV risk prevention can be provided to you through the health educators at Open Arms  
Healthcare Center 
Costs
There will not be any additional costs to you if you participate in this study.
Research-related injury
In the case of injury or illness resulting from your participation in this study, medical  
treatment is available to you at the University of Mississippi [INVESTIGATOR_60584].  You will be  
charged the usual and customary charges for any such treatment you receive.
Compensation
You will receive:
•$[ADDRESS_665347] visit. 
•$40 for completing each follow-up visit (5 and 17 weeks)
•$[ADDRESS_665348]  
information (prior to week 5’s visit), and
•$[ADDRESS_665349]  
information (prior to week 17’s visit) 
Voluntary Participation     
Your participation in this study is voluntary.  If at any point you decide to discontinue  
participation in this study, you will not suffer a penalty or loss of benefits to which you  
are otherwise entitled. 
Withdrawal
University of Mississippi [INVESTIGATOR_513583]00003630
Protocol: 2017-0169
Approved: 05/05/2020
Expi[INVESTIGATOR_6054]: 05/04/[ADDRESS_665350] your willingness to participate. 
Confidentiality
Every effort will be made to keep the information we learn about you private. 
Study personnel, the study sponsor, (Lifespan, National Institute of Child Health 
and Human Development and  the National Institutes of Health), the Food and 
Drug Administration (FDA),  the Office for Human Research Protections (OHRP) 
and the University of Mississippi [INVESTIGATOR_60584]’s Office of Grants and 
Contracts, Institutional Review Board (IRB) and Office of Integrity and 
Compliance may review the study records.
Protected Health Information
Protected health information is any personal health information through which 
you can be identified. The information collected in this study includes: your 
name, address, ZIP code, phone number, health insurance, education  level, 
information related to risk behaviors, medical record number,  clinical history, and 
lab results. A decision to participate in this research means that you agree to the 
use of your health information for the study described in this form. This 
information will not be released beyond the purposes of conducting this study. 
The information collected for this study will be kept indefinitely. While this study is  
ongoing you may not have access to research information, but you may request it  
after the research is completed. 
If the study results are published your name [CONTACT_513588].
Your medical information and records, once disclosed, may be re-
disclosed and may no longer be protected by [CONTACT_513586]. Portability and Accountability Act (HIPAA), which is 
a federal regulation designed to protect medical information, including 
medical information and records created through research.
You have the right to cancel this authorization at any time by [CONTACT_513587] [INVESTIGATOR_513583]00003630
Protocol: 2017-0169
Approved: 05/05/2020
Expi[INVESTIGATOR_6054]: 05/04/[ADDRESS_665351] to cancel the authorization at the 
following address: [CONTACT_513590], University of Mississippi [INVESTIGATOR_287496], [ADDRESS_665352], Jackson, MS [ZIP_CODE] or you may call (601)  
984-5560 (answering service will take calls after hours and on weekends).  
If you cancel this authorization, medical information and records about you 
that were created before the authorization was cancelled will still be used 
and disclosed as needed to preserve the integrity of the study.
If you do not sign this consent document, you will not be allowed to 
participate in this study.
Number of Participants
We expect [ADDRESS_665353]. Leandro Mena at [PHONE_10658] (the answering service will take  
calls after hours and on weekends).  
You may discuss your rights as a research participant with the Chairman of the  
University of Mississippi [INVESTIGATOR_60584]’s Institutional Review Board, [ADDRESS_665354], Jackson, Mississippi  [ZIP_CODE]; telephone, [PHONE_10659]; facsimile, [PHONE_10660].  
The Institutional Review Board is a group of people not involved with this study who  
have reviewed the study to protect your rights. 
You will be given a copy of this consent document to keep for your records after it has  
been signed.
Statement of Participation
I have been told about this study and the possible risks and benefits.  My participation is  
voluntary and I may withdraw at any time without any penalty or loss of benefits to  
which I am entitled, including medical care at the University of Mississippi [INVESTIGATOR_513584].
By [CONTACT_3368] I am not giving up any legal I may have.  
________________________________
Participant’s Printed Name
[CONTACT_513589] [INVESTIGATOR_513583]00003630
Protocol: 2017-0169
Approved: 05/05/2020
Expi[INVESTIGATOR_6054]: 05/04/2021
________________________________
Participant’s Signature
____________________________
Date
__________________________________________
Printed Name [CONTACT_50660]
__________________________________________
Signature [CONTACT_50660]
________________________________
Date
I acknowledge that the participant identified above has been entered into this study, with  
properly obtained informed consent.
________________________________
Signature [CONTACT_7919] 
________________________________
Date
University of Mississippi [INVESTIGATOR_513583]00003630
Protocol: 2017-0169
Approved: 05/05/2020
Expi[INVESTIGATOR_6054]: 05/04/2021